Business Context and Reporting Period
This Form 8-K is a current report filed by Miragen Therapeutics, Inc. (not Viridian Therapeutics, Inc.) on June 5, 2017. The registrant is a Delaware corporation headquartered in Boulder, Colorado, and is classified as an emerging growth company. The filing reports a specific corporate event rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As this is an event-driven report regarding clinical trial results, no financial statements or quantitative financial metrics are included in the document.
Material Changes
The material event reported is the announcement of interim results from the Phase 1 clinical trial for the Company's product candidate, MRG-106. This announcement was made via a press release issued on June 5, 2017, which is incorporated into the filing as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future performance, or a detailed risk factor analysis within the text provided. The primary focus is the disclosure of the clinical trial milestone. Investors should refer to the attached press release (Exhibit 99.1) for details on the trial results and any associated implications.
Key Facts for Investor Verification
- Verify the specific interim results of the Phase 1 clinical trial for MRG-106 by reviewing the press release filed as Exhibit 99.1.
- Confirm the company name is Miragen Therapeutics, Inc., as the input metadata referenced Viridian Therapeutics, Inc.
- Note that no financial data (revenue, cash, debt) is disclosed in this specific filing.
- Check subsequent filings for any updates on the clinical trial or financial impact of the development progress.